ubidecarenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4607	303-98-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: neuquinon ubidecarenone Vitamin Q	prevents hemorrhagic state Molecular weight: 863.37 Formula: C59H90O4 CLOGP: 12 LIPINSKI: 2 HAC: 4 HDO: 0 TPSA: 52.60 ALOGS: -6.65 ROTB: 31

Molecule

Description

Molfile Inchi Smiles

Synonyms:

neuquinon
ubidecarenone
Vitamin Q

prevents hemorrhagic state

Molecular weight: 863.37
Formula: C59H90O4
CLOGP: 12
LIPINSKI: 2
HAC: 4
HDO: 0
TPSA: 52.60
ALOGS: -6.65
ROTB: 31

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Muscle spasticity	419.19	14.14	180	18788	19780	56253319
Ear pain	370.19	14.14	189	18779	30701	56242398
Respiratory disorder	342.11	14.14	185	18783	33772	56239327
Body temperature increased	332.33	14.14	182	18786	34060	56239039
Night sweats	324.39	14.14	191	18777	41022	56232077
Insomnia	171.73	14.14	263	18705	191597	56081502
Back pain	160.99	14.14	287	18681	236883	56036216
Urticaria	158.03	14.14	218	18750	144458	56128641
Sinusitis	156.32	14.14	256	18712	197325	56075774
Peripheral swelling	150.32	14.14	277	18691	234449	56038650
Lower respiratory tract infection	132.90	14.14	178	18790	114616	56158483
Asthenia	131.98	14.14	329	18639	342644	55930455
Pruritus	118.89	14.14	301	18667	316322	55956777
Abdominal pain upper	112.21	14.14	209	18759	178104	56094995
Diarrhoea	75.87	14.14	418	18550	638089	55635010
Joint swelling	60.89	14.14	225	18743	289575	55983524
Toxicity to various agents	60.04	14.14	4	18964	224560	56048539
Headache	59.72	14.14	356	18612	558688	55714411
Rash	59.21	14.14	324	18644	492723	55780376
Incorrect route of product administration	42.95	14.14	44	18924	21285	56251814
Rheumatoid arthritis	41.16	14.14	41	18927	382563	55890536
Pain	34.67	14.14	358	18610	662826	55610273
Acute kidney injury	31.84	14.14	21	18947	240742	56032357
Exposure during pregnancy	29.90	14.14	5	18963	136337	56136762
General physical health deterioration	29.89	14.14	10	18958	170000	56103099
Fatigue	28.99	14.14	398	18570	788154	55484945
Maternal exposure during pregnancy	28.69	14.14	14	18954	189539	56083560
Infusion related reaction	27.92	14.14	18	18950	208913	56064186
Vomiting	25.98	14.14	269	18699	497959	55775140
Treatment failure	25.16	14.14	13	18955	170379	56102720
Full blood count decreased	25.13	14.14	35	18933	23314	56249785
Systemic lupus erythematosus	23.40	14.14	16	18952	180062	56093037
Pemphigus	21.75	14.14	13	18955	157199	56115900
Myalgia	21.63	14.14	95	18873	131930	56141169
Drug ineffective	20.40	14.14	205	18763	918784	55354315
Death	20.30	14.14	54	18914	341372	55931727
Muscle spasms	19.66	14.14	95	18873	137276	56135823
Hand deformity	18.78	14.14	11	18957	134481	56138618
Glossodynia	17.94	14.14	15	18953	152443	56120656
Low density lipoprotein increased	17.36	14.14	15	18953	5859	56267240
Mitochondrial DNA deletion	16.59	14.14	3	18965	10	56273089
Hypokalaemia	15.83	14.14	6	18962	94431	56178668
Weight increased	15.41	14.14	131	18837	229572	56043527
Seizure	15.11	14.14	12	18956	125107	56147992
Irritable bowel syndrome	15.02	14.14	54	18914	68404	56204695
Overdose	14.29	14.14	9	18959	105821	56167278

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Fatigue	78.16	16.20	231	8266	334975	31353872
Blindness cortical	41.29	16.20	11	8486	346	31688501
Asthenia	32.08	16.20	132	8365	224623	31464224
Full blood count decreased	24.45	16.20	26	8471	16514	31672333
Dysgeusia	23.19	16.20	30	8467	23436	31665411
Constipation	21.89	16.20	78	8419	123913	31564934
Toxicity to various agents	21.38	16.20	11	8486	181476	31507371
Abdominal discomfort	20.82	16.20	44	8453	51523	31637324
Protein total increased	19.01	16.20	10	8487	2165	31686682
Dizziness	18.89	16.20	104	8393	199043	31489804
Peripheral swelling	18.80	16.20	50	8447	67815	31621032
Diarrhoea	17.97	16.20	158	8339	352251	31336596
Tendon calcification	17.30	16.20	4	8493	69	31688778
Myalgia	16.64	16.20	52	8445	77206	31611641

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Muscle spasticity	191.50	13.59	100	20627	19589	70888128
Ear pain	180.52	13.59	108	20619	27491	70880226
Night sweats	153.02	13.59	116	20611	43568	70864149
Respiratory disorder	135.06	13.59	103	20624	39020	70868697
Body temperature increased	133.41	13.59	103	20624	39731	70867986
Back pain	99.21	13.59	234	20493	270918	70636799
Insomnia	88.52	13.59	196	20531	217610	70690107
Peripheral swelling	84.16	13.59	202	20525	236361	70671356
Asthenia	81.73	13.59	306	20421	457360	70450357
Toxicity to various agents	68.84	13.59	14	20713	382158	70525559
Sinusitis	67.28	13.59	151	20576	169044	70738673
Fatigue	59.76	13.59	428	20299	823891	70083826
Pruritus	53.43	13.59	221	20506	345339	70562378
Urticaria	52.39	13.59	134	20593	162915	70744802
Abdominal pain upper	51.10	13.59	148	20579	193454	70714263
Diarrhoea	50.08	13.59	395	20332	782946	70124771
Lower respiratory tract infection	46.84	13.59	102	20625	111811	70795906
Completed suicide	46.04	13.59	6	20721	227129	70680588
Myalgia	40.17	13.59	124	20603	167768	70739949
General physical health deterioration	34.36	13.59	13	20714	236018	70671699
Headache	33.90	13.59	287	20440	580118	70327599
Rash	32.24	13.59	257	20470	510305	70397412
Drug abuse	32.08	13.59	3	20724	147253	70760464
Incorrect route of product administration	31.83	13.59	39	20688	26453	70881264
Blindness cortical	30.06	13.59	11	20716	912	70906805
Pain	29.67	13.59	297	20430	628519	70279198
Acute kidney injury	29.42	13.59	59	20668	474565	70433152
Overdose	27.05	13.59	8	20719	169737	70737980
Muscle spasms	24.11	13.59	99	20628	153947	70753770
Joint swelling	24.02	13.59	141	20586	253070	70654647
Full blood count decreased	23.69	13.59	32	20695	23886	70883831
Feeling abnormal	23.50	13.59	93	20634	142226	70765491
Drug interaction	21.47	13.59	50	20677	381391	70526326
Rheumatoid arthritis	20.07	13.59	34	20693	291771	70615946
Dysgeusia	19.43	13.59	44	20683	49458	70858259
C-reactive protein increased	17.99	13.59	5	20722	110512	70797205
MELAS syndrome	17.66	13.59	5	20722	181	70907536
Coma	17.28	13.59	3	20724	91841	70815876
Low density lipoprotein increased	17.01	13.59	16	20711	8049	70899668
Mitochondrial DNA deletion	16.59	13.59	3	20724	12	70907705
Pain in extremity	15.42	13.59	155	20572	327927	70579790
Intentional overdose	15.03	13.59	5	20722	98430	70809287
Hyponatraemia	14.74	13.59	15	20712	160072	70747645
Tendon calcification	14.15	13.59	4	20723	144	70907573
Flatulence	13.95	13.59	33	20694	38148	70869569
Contusion	13.92	13.59	74	20653	127962	70779755
Cardio-respiratory arrest	13.89	13.59	6	20721	100671	70807046
Treatment failure	13.86	13.59	13	20714	144129	70763588
Hypokalaemia	13.62	13.59	11	20716	131177	70776540

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01EB09	CARDIOVASCULAR SYSTEM CARDIAC THERAPY OTHER CARDIAC PREPARATIONS Other cardiac preparations
CHEBI has role	CHEBI:22586	antioxidants
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
CHEBI has role	CHEBI:173084	ferroptosis inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Congestive heart failure	indication	42343007	DOID:6000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D01065	KEGG_DRUG
4021303	VUID
N0000148739	NUI
4021303	VANDF
CHEBI:46245	CHEBI
U10	PDB_CHEM_ID
CHEMBL454801	ChEMBL_ID
C010524	MESH_SUPPLEMENTAL_RECORD_UI
3463	INN_ID
DB09270	DRUGBANK_ID
EJ27X76M46	UNII
21406	RXNORM
15490	MMSL
194138	MMSL
233517	MMSL
270084	MMSL
33141	MMSL
33199	MMSL
33200	MMSL
37841	MMSL
46285	MMSL
74202	MMSL
d04523	MMSL
003911	NDDF
012958	NDDF
412129003	SNOMEDCT_US
412130008	SNOMEDCT_US
C0041536	UMLSCUI
5281915	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
IQQU Acne Serum	HUMAN OTC DRUG LABEL	3	50403-226	LOTION	0.00 g	TOPICAL	UNAPPROVED DRUG OTHER	9 sections
Vita-Rx Diabetic Vitamin	HUMAN PRESCRIPTION DRUG LABEL	14	65121-301	CAPSULE, GELATIN COATED	50 mg	ORAL	unapproved drug other	5 sections
Vita-Rx Diabetic Vitamin	HUMAN PRESCRIPTION DRUG LABEL	14	69677-050	CAPSULE, GELATIN COATED	50 mg	ORAL	unapproved drug other	5 sections
Zyrexal	HUMAN PRESCRIPTION DRUG LABEL	8	72380-915	TABLET	75 mg	ORAL	unapproved drug other	8 sections